GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Speaking at The New York Times’s DealBook Summit, Eli Lilly’s chief executive and an obesity medicine specialist discussed ...

Fact checked by Nick Blackmer GLP-1 medications like Ozempic and Wegovy have become popular for helping people lose weight or ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

GLP-1s (glucagon-like peptide-1 receptor agonists) are medications used to treat type 2 diabetes and obesity. You’ve probably ...